Skip to main content

Table 1 Characteristics of patients in forceps biopsy for biliary stricture

From: Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer

 

Total (n = 79)

Malignant (n = 65)

Benign (n = 14)

P a

Age (years)

68.59 ± 12.02

69.15 ± 11.15

66.00 ± 15.66

0.376

Sex (male to female)

53:26

44:21

9:5

0.806

Chief complaint

    

 Jaundice

52 (66 %)

44 (68 %)

8 (57 %)

0.450

 Pain

3 (4 %)

2 (3 %)

1 (7 %)

0.470

 Cholangitis

19 (24 %)

15 (19 %)

4 (29 %)

0.663

 Stent exchange

2 (3 %)

2 (3 %)

0 (0 %)

0.506

 CBD dilatation

2 (3 %)

1 (2 %)

1 (7 %)

0.226

 Pancreatitis

1 (1 %)

1 (2 %)

0 (0 %)

0.640

Total bilirubin (mg/dL)

8.43 ± 6.33

9.14 ± 6.47

4.87 ± 4.18

0.025*

CEA (ng/mL)

18.90 ± 57.73

20.58 ± 60.95

6.08 ± 9.78

0.566

CA 19-9 (U/mL)

1863.70 ± 5062.73

2122.58 ± 5736.81

88.54 ± 75.95

0.325

ALKP (U/L)

365.65 ± 320.33

367.86 ± 322.48

352.80 ± 324.09

0.892

Stricture level (CBD:CHD)

54:25

42:23

12:2

0.124

  1. Abbreviations: CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, ALKP alkaline phosphatase, CBD common bile duct, CHD common hepatic duct
  2. aComparison between malignant and benign group
  3. *P<0.05